搜索
 > 【CD44】重组蛋白信息

CD44信息

英文名称:CD44 antigen
中文名称:CD44抗原
靶点别称:MDU2,CD44,Epican,Extracellular matrix receptor III,HUTCH-I,Hermes antigen,Phagocytic glycoprotein 1,MDU3,MIC4,Heparan sulfate proteoglycan,LHR ,CDw44,PGP-I,CD44 antigen,GP90 lymphocyte homing/adhesion receptor,CD_antigen=CD44,Hyaluronate receptor,Phagocyt
上市药物数量:0
临床药物数量:17
最高研发阶段:临床二期

CD44产品列表

产品库
物种
属性
货号 物种 产品描述 蛋白结构 纯度 活性
CD4-H5226
Human
Human CD44 Protein, His Tag
PG1-H5255
Human
Human CD44 Protein, Fc Tag (HPLC-verified)
 
评论(0)
 

CD44 分子别名

CD44,CDW44,CSPG8,ECMR-III,HCELL,HUTCH-I,IN,LHR,MC56,MDU2,MDU3,MIC4,Pgp1,Epican

CD44 分子背景

CD44 antigen is a cell-surface glycoprotein involved in cell–cell interactions, cell adhesion and migration. CD44 is expressed in a large number of mammalian cell types. CD44 is a receptor for hyaluronic acid and can also interact with other ligands, such as osteopontin, collagens, and matrix metalloproteinases (MMPs). CD44 function is controlled by its posttranslational modifications. One critical modification involves discrete sialofucosylations rendering the selectin-binding glycoform of CD44 called HCELL (for Hematopoietic Cell E-selectin/L-selectin Ligand). CD44 participates in a wide variety of cellular functions including lymphocyte activation, recirculation and homing, hematopoiesis, and tumor metastasis. Transcripts for this gene undergo complex alternative splicing that results in many functionally distinct isoforms.

CD44 参考文献

CD44临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
VB1-050 (Sesen Bio) VBX-050; VB1-050,VBX 050; VB1 050,VBX050; VB1050 临床前 Sesen Bio 结肠癌, 胃癌, 前列腺癌, 肝癌
Hyaluronic acid/Fluorouracil 临床二期 莫纳什大学, Alchemia 转移性结直肠癌
Hyaluronic acid (Actelion) CTX-100; ETX-100 临床一期 爱可泰隆 α1抗胰蛋白酶缺乏症, 哮喘 详情
RG-7356 RG-7356; RO-5429083 临床一期 中外制药, 罗氏 实体瘤, 急性骨髓性白血病 详情
VB-4011 (Sesen Bio) VB-4011 临床前 Viventia Biotech, Sesen Bio 癌症
Bivatuzumab mertansine BIWI-1 临床一期 勃林格殷格翰, ImmunoGen 乳腺癌, 头颈癌 详情
VB1-008 (Sesen Bio) VB1-008; VBX-008,VB1 008; VBX 008,VB1008; VBX008 临床前 Sesen Bio 癌症
NP-1 (Sesen Bio) NP-1 (Sesen Bio),NP 1 (Sesen Bio),NP1 (Sesen Bio) 临床前 Sesen Bio 癌症
Bivatuzumab BIWA-4; anti-CD44; anti-CD44 monoclonals 临床二期 勃林格殷格翰 头颈癌 详情
MLM-CAR44.1 T-cell therapy (MolMed) 临床二期 MolMed 多发性骨髓瘤, 急性骨髓性白血病 详情
VB-6008 (Sesen Bio) VB-6008 临床前 Viventia Biotech, Sesen Bio 癌症
CA-102N CA-102N 临床一期 BioBud 结肠直肠癌 详情
SM-8849 SM-8849 临床二期 大日本住友 类风湿性关节炎 详情
AMC-303 AMC-303 临床一期 Amcure 实体瘤 详情
VB-6050 (Sesen Bio) VB-6050 临床前 Viventia Biotech, Sesen Bio 癌症
BV-5200 BV-5200; HYAL-BV5200 临床二期 SkyePharma 冠状动脉再狭窄
PF-3475952 PF-03475952; PF-3475952 临床一期 辉瑞 类风湿性关节炎

消息提示

请输入您的联系方式,再点击提交!

确定